Skip to main content
Sailong Pharmaceutical Group Co., Ltd. logo

Sailong Pharmaceutical Group Co., Ltd. — Investor Relations & Filings

Ticker · 002898 ISIN · CNE1000032S5 LEI · 8368004F5Y6BSB6US681 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,116 across all filing types
Latest filing 2021-09-03 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002898

About Sailong Pharmaceutical Group Co., Ltd.

https://www.sailong.cn

Sailong Pharmaceutical Group Co., Ltd. is a pharmaceutical enterprise focused on the research, development, production, and marketing of high-end generic drugs and innovative formulations. The company maintains an integrated industrial chain encompassing active pharmaceutical ingredients (APIs) and finished dosage forms. Its product portfolio primarily targets therapeutic areas such as cardiovascular and cerebrovascular diseases, the digestive system, and anti-infective treatments. Key products include Monosialotetrahexosylganglioside Sodium Injection and Pantoprazole Sodium for Injection. The group emphasizes technological innovation and quality control to provide clinical solutions for complex medical conditions.

Recent filings

Filing Released Lang Actions
关于完成工商变更登记的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the completion of a business registration change, specifically a company name change and related registration details. It includes no financial data, no report content, and no mention of financial results or filings. It is a regulatory announcement about corporate information update, not a report or financial filing. Therefore, it fits best under Regulatory Filings (RNS). The document length is short and it is an announcement, not a report itself.
2021-09-03 Chinese
关于公司控股股东部分股份解除质押的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the partial release of pledged shares by the company's controlling shareholder. It details the number of shares released from pledge, the shareholder's total holdings, and the status of pledged shares. There is no financial statement, earnings data, or management discussion. The document is a regulatory announcement about share pledge status, which fits the category of Regulatory Filings (RNS) as it does not fit into more specific categories like share issue or director dealings. The document length is short and it is a formal disclosure of share pledge status, typical of regulatory filings.
2021-08-31 Chinese
关于持股5%以上的股东减持股份预披露公告
Major Shareholding Notification Classification · 100% confidence The document is a public announcement regarding a shareholder holding more than 5% of the company's shares planning to reduce their holdings. It details the shareholder's identity, the number and percentage of shares held, the planned reduction amount, reasons for reduction, methods, timing, and legal compliance. This type of document is a notification about a major shareholding change, specifically a reduction in shares held by a significant shareholder. It is not a financial report, earnings release, or management discussion. It fits the definition of 'Major Shareholding Notification' (MRQ). The document length is short and focused on this specific announcement, confirming it is not a full report or other category. Therefore, the correct classification is MRQ with high confidence.
2021-08-30 Chinese
关于会计政策变更的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Zhuhai Sailong Pharmaceutical Co., Ltd. regarding a change in accounting policy related to the adoption of a new lease accounting standard effective from January 1, 2021. It details the reasons for the change, the approval process by the board and supervisory committee, and includes independent directors' and supervisory opinions. The document is relatively short (2162 characters) and does not contain financial statements or detailed financial data. It is an announcement about a change in accounting policy rather than a full financial report or audit report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for regulatory announcements that do not fit other specific categories.
2021-08-25 Chinese
2021年半年度募集资金存放与使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the use and management of funds raised through an initial public offering (IPO) by Zhuhai Sailong Pharmaceutical Co., Ltd. It includes specifics on the amount raised, usage of funds during the half-year period ending June 30, 2021, project progress, and compliance with regulatory requirements. The document is titled as a "2021 Half-Year Special Report on the Deposit and Use of Raised Funds" and contains financial figures, project status, and regulatory approvals. It is not a general annual or quarterly financial report but a specialized report focused on the use of IPO proceeds. This type of document corresponds to a Capital/Financing Update (CAP) as it provides updates on fundraising and the use of capital raised.
2021-08-25 Chinese
独立董事关于控股股东及其他关联方占用公司资金、公司对外担保情况的专项说明和独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on matters discussed at the company's third board of directors' fifth meeting. It includes independent opinions on external guarantees, related party fund occupation, the use of raised funds for the half-year period ending June 30, 2021, and accounting policy changes. The document references compliance with regulatory bodies such as the China Securities Regulatory Commission and Shenzhen Stock Exchange rules. The content is focused on governance and compliance opinions rather than full financial statements or detailed financial results. The document length is short (1351 characters), and it is a formal opinion related to board meeting matters, not a full report or announcement of a report. This fits best under Board/Management Information (MANG), which covers announcements related to board or senior management matters, including independent directors' opinions on board meeting items.
2021-08-25 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.